The guidelines for treatment of prostate cancer using the HDR-brachytherapy approved during the expert meeting on are presented in this article. The references are given to the guidelines for the technology of prostate brachytherapy. The questions of the diagnostics and patient selection for HDR-brachytherapy are discussed, indications and contraindications are defined for the brachytherapy. Absolute contraindications for brachytherapy are outlined. The treatments strategy is evaluated with regard to the prostate cancer progression risk. The quality control criteria and are presented. Recommendations For patients with lowrisk prostate cancer who require or choose active treatment, HDR-brachytherapy alone should be offered to eligible patients. For patients with intermediate-risk prostate cancer choosing HDR-brachytherapy with or without androgen-deprivation therapy or EBRT and brachytherapy boost should be offered to eligible patients. For patients with high-risk prostate cancer receiving EBRT and prolonged androgen-deprivation therapy, HDR-brachytherapy boost should be offered to eligible patients. The procedure stages including planning, preoperative dosimetry, technique, anesthesia, and possible complications and their prophylaxis are described. The optimal doses limits and fractions are also outlined.

Authors declare lack of the possible conflicts of interest